The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
Abstract
BACKGROUND: In invasive breast cancer, HER2 is a well-established negative prognostic factor. However, its significance on the prognosis of ductal carcinoma in situ (DCIS) of the breast is unclear. As a result, the impact of HER2-directed therapy on HER2-positive DCIS is unknown and is currently the subject of ongoing clinical trials. In this study, we aim to determine the possible impact of HER2-directed targeted therapy on survival outcomes for HER2-positive DCIS patients.
MATERIALS AND METHODS: The National Cancer Data Base (NCDB) was used to retrieve patients with biopsy-proven DCIS diagnosed from 2004–2015. Patients were divided into two groups based on the adjuvant therapy they received: systemic HER2-directed targeted therapy or no systemic therapy. Statistics included multivariable logistic regression to determine factors predictive of receiving systemic therapy, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS.
RESULTS: Altogether, 1927 patients met inclusion criteria; 430 (22.3%) received HER2-directed targeted therapy; 1497 (77.7%) did not. Patients who received HER2-directed targeted therapy had a higher 5-year OS compared to patients that did not (97.7% vs. 95.8%, p = 0.043). This survival benefit remained on multivariable analysis. Factors associated with worse OS on multivariable analysis included Charlson-Deyo Comorbidity Score ≥ 2 and no receipt of hormonal therapy.
CONCLUSION: In this large study evaluating HER2-positive DCIS patients, the receipt of HER2-directed targeted therapy was associated with an improvement in OS. The results of currently ongoing clinical trials are needed to confirm this finding.
Keywords: DCISHER2molecular statustargeted therapybreast cancer
References
- WHO Classification of Tumours Editorial Board. Breast Tumours: WHO Classification of Tumours, 5th ed. International Agency for Research on Cancer, Lyon 2019.
- Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions. Arch Pathol Lab Med. 2013; 137(4): 462–466.
- Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69(1): 7–34.
- Siziopikou KP, Anderson SJ, Cobleigh MA, et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013; 142(2): 415–421.
- Page D, Dupont W, Rogers L, et al. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer. 1982; 49(4): 751–758, doi: 10.1002/1097-0142(19820215)49:4<751::aid-cncr2820490426>3.0.co;2-y.
- Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004; 350(14): 1430–1441.
- Williams KE, Barnes NLP, Cramer A, et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 2015; 26(5): 1019–1025.
- Takahashi S, Thike AA, Koh VC, et al. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Arch. 2018; 473(3): 275–283.
- Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353(9169): 1993–2000.
- Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16(2): 441–452.
- Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012; 30(12): 1268–1273.
- Borgquist S, Zhou W, Jirström K, et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. 2015; 15: 468.
- Davis JE, Nemesure B, Mehmood S, et al. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Appl Immunohistochem Mol Morphol. 2016; 24(1): 20–25.
- Poulakaki N, Makris GM, Battista MJ, et al. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast? Breast. 2016; 25: 57–61.
- Daoud SA, Ismail WM, Abdelhamid MS, et al. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. Asian Pac J Cancer Prev. 2016; 17(8): 3733–3736.
- Mustafa RE, DeStefano LM, Bahng J, et al. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. Ann Surg Oncol. 2017; 24(10): 2999–3003.
- Di Cesare P, Pavesi L, Villani L, et al. The Relationships between HER2 Overexpression and DCIS Characteristics. Breast J. 2017; 23(3): 307–314.
- Lewis GD, Haque W, Butler EB, et al. Survival Outcomes and Patterns of Management for Anal Adenocarcinoma. Ann Surg Oncol. 2019; 26(5): 1351–1357.
- Lewis GD, Haque W, Verma V, et al. The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer. Bladder Cancer. 2018; 4(2): 205–213.
- Lewis GD, Xing Y, Haque W, et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun (Lond). 2019; 39(1): 60.
- Lewis GD, Dalwadi SM, Farach A, et al. The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma. Ann Surg Oncol. 2019; 26(6): 1879–1885.
- Lewis GD, Xing Y, Haque W, et al. The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast J. 2019; 25(6): 1171–1176.
- Cancer program standards: Ensuring patient-centered care. 2016 ed. https://www.facs.org/~/media/files/quality%20programs/cancer/coc/2016%20coc%20standards%20manual_interactive%20pdf.ashx.
- Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 2004; 100(11): 2317–2327.
- Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol. 2005; 18(5): 615–620.
- Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol. 2001; 70(3): 303–316.
- Kuerer HM, Buzdar AU, Mittendorf EA, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011; 117(1): 39–47.
- Parham DM, Pinder SE. The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast. Histopathology. 2017; 70(6): 1009–1011.
- Gunia SR, Patel MS, Mamounas EP. Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature. Case Rep Surg. 2012; 2012: 454273.
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9): 2639–2648.
- Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16): 1659–1672.
- Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25(6): 634–641.
- Wolff AC, Hammond ME, Hicks DG, et al. American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014; 138(2): 241–256.
- Wolff AC, Hammond ME, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11): 1364–1382.